Serum from Dog with Eye Tumor for Disease Research

Description

This study aimed to determine if topical application of undiluted heterologous serum could improve the healing time of superficial chronic corneal epithelial defects (SCCEDs) in dogs. The study was a multicenter, randomized, double-masked, controlled clinical trial involving 41 client-owned dogs. The dogs were randomly assigned to receive either topical undiluted heterologous serum or isotonic saline, along with tobramycin and atropine. Epithelial debridement was performed at all visits, and grid keratotomy was performed at visits 2, 3, and 4. Ophthalmic examinations were conducted weekly for four weeks, or until corneal reepithelialization was achieved. The results showed that there was no significant difference in healing time between the serum-treated group and the placebo group. All SCCEDs in both groups healed within 4 weeks. The study concluded that while topical application of undiluted heterologous serum was well-tolerated, it did not reduce the time to corneal reepithelialization when used with standard treatments. [Ref: Eaton, J. S., Hollingsworth, S. R., Holmberg, B. J., Brown, M. H., Smith, P. J., & Maggs, D. J. (2017). Effects of topically applied heterologous serum on reepithelialization rate of superficial chronic corneal epithelial defects in dogs. Journal of the American Veterinary Medical Association, 250(9), 1014–1022. https://doi.org/10.2460/javma.250.9.1014]

Details

Industries:

Cancer Research

Related product to Serum from Dog with Eye Tumor for Disease Research

Serum from Dog with Eye Tumor for Disease Research is a Use Case of:

Product

Canine Serum - Eye Tumor

Go to product

Your contact person

Interested in this use case? An employee of Lab4Paws is at your disposal.

Davide Confalonieri, PhD

CEO

More Use Cases of Lab4Paws

Get insights into the use cases of Lab4Paws

Use Case

Animal PBMCs for Antibody Discovery

Antibody Production

PBMCs are used in antibody discovery due to their role in the immune response. Antibody-secreting cells (ASCs), a type of PBMC, are an excellent source of high-affinity antibodies with therapeutic potential. Millions of PBMCs can be isolated and screened to identify antigen-specific ASCs that secrete antibodies with desirable properties. One method involves microfluidic encapsulation of single ASCs into an antibody capture hydrogel, followed by antigen bait sorting using flow cytometry, enabling the rapid discovery of monoclonal antibodies. These antibodies can then be further characterized for their binding affinity and neutralizing capacity, making PBMCs a valuable resource for developing antibody-based drugs and studying immune responses. [Ref: Fischer, K., Lulla, A., So, T.Y. et al. Rapid discovery of monoclonal antibodies by microfluidics-enabled FACS of single pathogen-specific antibody-secreting cells. Nat Biotechnol (2024). https://doi.org/10.1038/s41587-024-02346-5]

Use Case

Beagle PBMCs for Antibody Discovery

antibody production

Beagle PBMCs have been used to generate anti-canine CD20 antibodies, which can target B cells and B cell lymphoma cells. These antibodies are tested for their binding affinity and ability to induce cell death, showing promise as therapeutic antibodies for treating canine B cell lymphoma. [Ref: Mizuno, T., Kato, Y., Kaneko, M.K. et al. Generation of a canine anti-canine CD20 antibody for canine lymphoma treatment. Sci Rep 10, 11476 (2020). https://doi.org/10.1038/s41598-020-68470-9]

Use Case

Pig/Minipig PBMCs for Antibody Discovery

Antibody Production

Pig PBMCs have been used in antibody discovery to isolate antigen-specific B cells for monoclonal antibody (mAb) cloning. For example, researchers have established platforms to sort antigen-specific single B cells from immunized pigs, allowing for the direct cloning and expression of antigen-specific mAbs. Sequential vaccination of pigs with different serotypes of the foot-and-mouth disease virus (FMDV) enabled the isolation of broadly neutralizing antibodies (bnAbs) by dissecting B-cell receptor (BCR) gene repertoires from PBMCs. [Ref: Li, F., Wu, S., Lv, L., Huang, S., Zhang, Z., Zerang, Z., Li, P., Cao, Y., Bao, H., Sun, P., Bai, X., He, Y., Fu, Y., Yuan, H., Ma, X., Zhao, Z., Zhang, J., Wang, J., Wang, T., Li, D., … Li, K. (2024). Discovery, recognized antigenic structures, and evolution of cross-serotype broadly neutralizing antibodies from porcine B-cell repertoires against foot-and-mouth disease virus. PLoS pathogens, 20(10), e1012623. https://doi.org/10.1371/journal.ppat.1012623]